SoftOx Solutions AS - New Equity Research Report Published by Analyst Group

SoftOx Solutions AS ("SoftOx") announces that Analyst Group has published an updated equity research report covering the Company.

The report provides an independent assessment of SoftOx's clinical development programmes, market opportunities, strategic alternatives, and valuation ahead of the anticipated Phase 2a proof-of-concept readout in H1 2027.

The full report is available here: https://analystgroup.se/bolag/softox-solutions/softox-solutions

The analysis has been prepared by Analyst Group. The assessments, assumptions, and valuations expressed in the report are those of Analyst Group and do not constitute guidance or forecasts issued by SoftOx Solutions AS.

For further information, please contact: Ulrik Spork, COB, Soft Solutions AS, +45 31 38 83 87 Ingrid Juven, CFO, SoftOx Solutions AS, +47 918 76 165 Mail: ir@soft-ox.com

About SoftOx Solutions AS: SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective therapy for the treatment of respiratory infections in the airways and lungs. The Company is listed on Euronext Growth Oslo.